The in-licensing arm of an Asia-based pharma company with several US offices is seeking partnerships with companies based in the USA.

The firm seeks specialty biotech therapeutics in neurobiology, dermatology, respiratory, oncology and ophthalmology indications. The firm focuses on technology that are 2-3 years from the market and with a 505(b) (2) regulatory pathway. The firm will consider in-licensing and acquisitions in these specialty areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Japan-based corporate VC fund primarily makes early stage investments solely in the Life Sciences. The firm raised a new fund in 2014 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally, but at present has a primary focus on opportunities in the USA. The firm acts as a co-investor.

The fund focuses on therapeutic drug discovery platforms. For therapeutics, the firm looks for small molecules, biologics, as well as biosimilars and reformulated drugs. The firm is opportunistic in terms of indications and is particularly interested in orphan indications and in products that are targeting Japan as a future market. The firm will consider products in all stages of development, but typically invests in products that are in pre-clinical and early-clinical stages.

The firm will only co-invest with other institutional investors in opportunities outside of Japan; companies backed solely by angel investors are not of interest. The firm prefers opportunities with a syndicate and/or lead investor in place. The firm typically requests board observation rights in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Massachusetts has two funds under management and is currently investing out of its second fund. The firm seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $2 million to $4million. The firm plans to invest in 2-4 companies over the next 12 months and prefers to invest in companies based in US or Canada.

The firm is currently looking for new investment opportunities in life sciences. The firm is interested in therapeutic platform technologies from an early stage of development, and is also interested in healthcare IT, device and diagnostic companies that are generating at least $2 million in revenue. The firm is currently not interested in single asset therapeutics or pre-revenue diagnostics/medical devices.

The firm generally seeks to invest in private companies. The firm has no specific requirements for the company’s management team, and sometimes takes a board seat when investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Life Science focused investment fund based in Shanghai, China was founded by successful Chinese and American entrepreneurs in the healthcare industry. The fund primarily considers investments based in China or has a significant China nexus. For example, the company must have a principal market in China, or R&D/manufacturing/sales in China. The fund prefers to follow and take minority stake. Investment size varies but typically ranges from US$1-4 million. The fund prefers business models that are marketing/sales oriented (vs. technology oriented). The fund is actively seeking new investment opportunities.

Currently the fund is looking for innovative antibiotics or alternatives to antibiotics in human health, animal health, and agriculture. For the stage of development, the fund seeks products that are able to enter the market within 2 years post investment. Historically, the fund invested in a medical supplier, medical devices, and AgBio.

The fund seeks an experienced management team that has “done it before.” The fund will consider US-based companies as long as the China nexus criteria is met. The firm seeks to make minority investment and typically requires China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate VC based in Shanghai, China with a recently established U.S. branch in California manages a $100M fund and typically invests $500K-$1M per company with the ability for acquisition at up to $100M. The fund is particularly seeking U.S.-based companies with innovative technologies to bring to the China market, and supports FDA-approved companies to gain CFDA approval.

The firm is seeking truly innovative medical devices and diagnostics in women’s health (OBGYN), neonatal healthcare, geriatric pregnancy, and other women’s health indications; women and children health-related products or services; life science-related products to be used in the research field; diagnostic kits; and immunotherapy and cell therapy services. The firm is not interested in pharmaceuticals or biotech therapeutics due to the longer development timeline, and particularly seeks late-stage technologies that are near or on-the-market generating revenue. The firm is open to all classes of devices.

The firm is seeking to invest or acquire private companies. Companies with products to be introduced to China is preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based investment firm has raised 2 funds to date and has recently closed its second fund in 2015. The firm invests at various stages—typically investing in Series A rounds or later. The firm is able to invest anywhere from USD 500K or more per company, and is flexible with the investment size depending on the deal. The firm has no set number of allocations it plans to make, but could invest in as many as 5-10 companies in the next 12 months. The firm both leads and coinvests. The firm invests globally, and is actively looking for new investment opportunities.

The firm invests in innovative medical technologies and digital health. In medtech, the firm is generally opportunistic in terms of the class of device and therapeutic areas. However, the firm is more interested in devices for cardiovascular and aging related diseases such as hypertension, Alzheimer’s, diabetes, etc; cosmetic devices; and sports medicine/rehabilitation. The device needs to target a high unmet medical need in China. The firm is interested in clinical to on-the-market products. The firm looks for POC therapeutics and devices, preferably with regulatory approval.

The firm may obtain a BOD seat depending on the opportunity. The firm is looking for companies with an exit strategy within 5 years post investment. The firm has the knowledge and know-how to help portfolio companies bring their respective products into the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A South Korea-based pharmaceutical company is interested in forming strategic partnerships with biopharmaceutical companies that are interested in entering the Korean market. The structure of the partnership includes in-licensing, co-marketing, co-promotion, join-ventures, and equity investment. The company is actively seeking new partnership opportunities.

The firm is currently seeking products in the following therapeutic areas: Cardiovascular disorder such as hypertension; Endocrinology disorder such as Type I, II Diabetes & Diabetic complications; CNS disorder such as Depression, Schizophrenia, Anxiety disorder, Insomnia, Alzheimer’s disease, Parkinson’s disease and Various pain types; Ophthalmic disorder; Respiratory disorder; Oncology disorder; Degenerative/Age-related diseases. The company prefers to invest in products that have attained human proof of concept, and is also interested in partnering with companies that have products on the market.

The firm will partner with companies from around the world that are interested in entering the Korean market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com